Scientists prioritize experimental therapies for Bundibugyo Ebola trials

Global health experts have prioritized several antiviral drugs and monoclonal antibodies for clinical trials against Bundibugyo virus disease (BVD), following a technical meeting convened to review potential medical countermeasures for the rare Ebola strain. The meeting focused on the current landscape of therapeutics for Bundibugyo virus disease and reviewed evidence for specific products including remdesivir,…

Wearable ultrasound patch could help detect pregnancy complications earlier, researchers say

Researchers at the University of Oxford have developed a wearable ultrasound patch that could allow doctors to continuously monitor a baby’s blood flow during pregnancy, potentially helping detect complications earlier and reduce the risk of stillbirth. The study, published May 26 in Nature Biotechnology, was led by Professor Antoniya Georgieva of Oxford’s Nuffield Department of…

Donors pledge over $800 million to kickstart Global Financing Facility investment round

Donors have pledged more than $800 million to launch a new investment round for the Global Financing Facility (GFF), a World Bank–hosted partnership aimed at accelerating reductions in maternal and child deaths. The GFF announced $806 million in new commitments from governments and philanthropic partners in support of its five-year TRANSFORM 2030 strategy, unveiled on…

Civil Society Calls for Greater Engagement in Rollout of HIV Prevention Drug Lenacapavir As Global Tensions Grow

Civil society organisations in Uganda have raised concerns over limited involvement in the planned rollout of a new long-acting antiretroviral drug, lenacapavir for HIV prevention, urging authorities to ensure inclusive planning and community engagement. The concerns emerged during a virtual meeting convened by HEPS-Uganda on March 17, 2026, which brought together 53 HIV prevention advocates.…

European Medicines Agency backs single dose drug that could end sleeping sickness

In a milestone for global health research, the European Medicines Agency (EMA) has issued a positive scientific opinion for acoziborole, a single-dose oral treatment for gambiense human African trypanosomiasis—better known as sleeping sickness. The disease, caused by the parasite Trypanosoma brucei gambiense and transmitted by the tsetse fly, has long plagued rural communities across sub-Saharan…